Focusing on microvascular disorders throughout the body, we have developed the world's first “vascular endothelial stem cells” as a cell-based therapeutic agent, providing a novel vascular regeneration treatment to reduce the risk of heart disease and dementia.
We operate “Doboku Sensei,” a web platform for civil engineering stakeholders that shares new methods and technologies to build sustainable, community-based infrastructure maintenance systems. By connecting municipalities with local communities, we establish a framework for transferring technical expertise and reducing maintenance costs.
EX-Fusion is Japan’s only private company dedicated to the commercialization of laser fusion reactors. This breakthrough technology has the potential to replace conventional energy sources and play a vital role in achieving carbon neutrality by 2050.
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
KDDD (Kyoto Drug Discovery and Development) is a spin-off company from Kyoto University. Our project is based on a result of research by Department of Ophthalmology Kyoto University and Graduate School of Biostudies. We sincerely aim to develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.
